锦波生物（832982）9月19日大宗交易平台出现一笔成交，成交量0.40万股，成交金额100.80万元，大宗 交易成交价为252.00元，相对今日收盘价折价14.86%。该笔交易的买方营业部为国金证券股份有限公司 上海静安区南京西路证券营业部，卖方营业部为国金证券股份有限公司深圳分公司。 进一步统计，近1个月内该股累计发生5笔大宗交易，合计成交金额为595.38万元。 证券时报·数据宝统计显示，锦波生物今日收盘价为295.98元，下跌0.84%，日换手率为0.79%，成交额 为1.44亿元，近5日该股累计下跌5.80%。 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | | | | | | | | （%） | | | | 0.40 | 100.80 | 252.00 | -14.86 | 国金证券股份有限公司上海静 安区南京西路证券营业部 | 国金证券股份有限 公司深圳分公司 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨 ...

（记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前核实。据此操作，风险自担。 每日经济新闻 每经讯，2025年9月19日，北交所上市公司锦波生物（832982，收盘价：295.98元）发生一笔大宗交易，成交价252元/股，成交 数量4000股，成交金额100.8万元，折价14.86%。买入营业部是国金证券股份有限公司上海静安区南京西路证券营业部，卖出营 业部是国金证券股份有限公司深圳分公司。 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-159 山西锦波生物医药股份有限公司 关于完成工商变更登记及公司章程备案的公告 2025 年 9 月 18 日 山西锦波生物医药股份有限公司（以下简称"公司"）于 2025 年 8 月 19 日 召开第四届董事会第十四次会议、2025 年 9 月 5 日召开 2025 年第四次临时股 东会，审议通过《关于取消监事会、修订〈公司章程〉并办理工商变更登记的 议案》等议案，具体内容详见于 2025 年 8 月 21 日在北京证券交易所指定信息 披露平台（https://www.bse.cn）披露的《关于取消监事会并修订〈公司章程〉 公告》（公告编号：2025-134）及 2025 年 9 月 8 日披露的《山西锦波生物医药 股份有限公司章程》（公告编号：2025-147）。公司于 2025 年 9 月 8 日召开第四 届董事会第十五次会议，审议通过《关于聘任杨霞女士为公司总经理的议案》 等议案，具体内容详见于 2025 年 9 月 8 日在北京证券交易所指定信息披露平台 （https://www.bse.cn）披露的《山西锦波生物医药股份有限公司董事、 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-158 山西锦波生物医药股份有限公司 2025 年半年度权益分派实施公告 一、权益分派方案 1、本公司 2025 年半年度权益分派方案为： 以公司现有总股本 115,065,340 股为基数，向全体股东每 10 股派 10 元人民 币现金。 2、扣税说明 （1）个人股东、投资基金适用股息红利差别化个人所得税政策,个人股东、 投资基金持股 1 个月（含 1 个月）以内，每 10 股补缴税款 2 元；持股 1 个月以 上至 1 年（含 1 年）的，每 10 股补缴税款 1 元；持股超过 1 年的，不需补缴税 款。 （2）对合格境外投资者股东，根据国税函[2009]47 号，公司按 10%的税率 代扣代缴所得税后，实际每 10 股派发 9 元。 （3）对于合格境外投资者之外的其他机构投资者和法人股东，本公司未代 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 山西锦波生物医药股份有限公司 2025 年半年度权益分派方案已获 2025 年 8 月 ...

证券时报•数据宝统计显示，锦波生物今日收盘价为298.48元，下跌0.41%，日换手率为1.10%，成交额 为2.03亿元，近5日该股累计下跌3.03%。 据天眼查APP显示，山西锦波生物医药股份有限公司成立于2008年03月28日。注册资本11506.534万人 民币。（数据宝） （原标题：锦波生物大宗交易成交0.65万股 成交额137.80万元） 锦波生物（832982）9月18日大宗交易平台出现一笔成交，成交量0.65万股，成交金额137.80万元，大宗 交易成交价为212.00元，相对今日收盘价折价28.97%。该笔交易的买方营业部为国金证券股份有限公司 上海静安区南京西路证券营业部，卖方营业部为国金证券股份有限公司深圳分公司。 进一步统计，近1个月内该股累计发生4笔大宗交易，合计成交金额为494.58万元。 9月18日锦波生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日 收盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | | | | | | | | （%） | ...

锦波生物（832982）9月17日大宗交易平台出现一笔成交，成交量0.64万股，成交金额137.60万元，大宗 交易成交价为215.00元，相对今日收盘价折价28.27%。该笔交易的买方营业部为国金证券股份有限公司 上海静安区南京西路证券营业部，卖方营业部为国金证券股份有限公司深圳分公司。 进一步统计，近1个月内该股累计发生3笔大宗交易，合计成交金额为356.78万元。 证券时报·数据宝统计显示，锦波生物今日收盘价为299.72元，下跌1.60%，日换手率为1.39%，成交额 为2.55亿元，近5日该股累计下跌2.65%。 据天眼查APP显示，山西锦波生物医药股份有限公司成立于2008年03月28日。注册资本11506.534万人 民币。（数据宝） 9月17日锦波生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | | | | | | | | （%） | | | | 0.64 | 137.60 | 215.00 | -28. ...

Group 1 - Mingya Fund announced that its public funds can invest in stocks listed on the Beijing Stock Exchange (BSE), becoming the second fund company to do so in September, following Zheshang Fund [1][2] - As of the second quarter report, 30 public fund companies have announced the ability to invest in BSE-listed stocks, with early entrants generally having larger asset management scales compared to later entrants [1][2] - The investment in BSE stocks is highlighted due to the different risk characteristics compared to the Shanghai and Shenzhen markets, necessitating full disclosure to protect investors' rights [2][3] Group 2 - A total of 60 BSE stocks have been heavily weighted in actively managed funds, with Jinbo Biological, Naconoer, Tongli Co., and Better Ray being among the most frequently held stocks [2] - Smaller funds have benefited from heavy allocations in BSE stocks, with some non-BSE themed funds also prioritizing BSE stocks in their portfolios, leading to improved performance [4] - The revenue data for BSE-listed companies has improved, with total revenue reaching 92.064 billion yuan in the first half of the year, reflecting a year-on-year growth of 6.01% [5][6]

Core Viewpoint - The speech by Yang Xia, Chairman of Jinbo Biotechnology, emphasizes the company's commitment to original innovation in the development and industrialization of recombinant human collagen, particularly focusing on type III collagen for medical and cosmetic applications [2][4]. Group 1: Original Innovation - Jinbo Biotechnology's academic name for its collagen is type A recombinant human collagen, which is used to develop various medical products and cosmetics, completing a closed-loop production and sales system [4]. - The company has focused on two main areas: life materials based on recombinant human collagen and antiviral products represented by anti-HPV biological proteins [4]. - In 2018, Jinbo Biotechnology discovered that type III collagen has a gene that regulates cell control and information transmission, leading to the world's first large-scale production of injectable recombinant type III human collagen using synthetic biology by 2021 [4][6]. Group 2: Technological Breakthroughs - In 2025, Jinbo Biotechnology received approval for injectable recombinant type III human collagen gel, the first of its kind produced through self-assembly and self-crosslinking technology using synthetic biology, achieving dual functions of filling and repairing against aging [6]. - Compared to traditional filling materials, this product significantly improves safety, manufacturing methods, and mechanisms of action, making it suitable for correcting mid-facial volume loss and contour defects [6][7]. - The company has achieved three breakthroughs: enhancing clinical safety of filling materials, innovating manufacturing methods through AI-driven synthetic biology, and innovating mechanisms of action to promote tissue regeneration and repair [7]. Group 3: Product and Patent Portfolio - Jinbo Biotechnology has established a comprehensive product chain and has obtained 157 patents related to its technologies [6][7].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company celebrates the fourth anniversary of its brand, Wei Yi Mei®, with over 2.7 million clinical applications and coverage of more than 4,000 medical institutions [6] - The launch of the new product combination, Wei Yi Mei® ColPlus, aims to enhance customer engagement and expand the sales channel through collaboration with Meituan [6] - The ColPlus product is designed for anti-aging targeting users aged 30 and above, offering a more precise solution for skin issues compared to previous products [6] - The online platform is becoming a significant channel for medical beauty consumption, with Meituan's data-driven marketing expected to improve user conversion rates [6] - The company is positioned to lead the collagen market by adapting to channel changes and expanding its online presence [6] - The financial forecast estimates the company's net profit to be 1.042 billion, 1.474 billion, and 1.867 billion yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 34, 24, and 19 [6] Financial Data and Profit Forecast - Total revenue is projected to grow from 1,443 million yuan in 2024 to 3,943 million yuan in 2027, with a compound annual growth rate of 22.7% [5] - The net profit is expected to increase significantly, with a growth rate of 144.3% in 2024 and 42.3% in 2025 [5] - The gross margin is forecasted to remain high, around 89.8% in 2025, indicating strong profitability [5]

| 代码 | | | 名称 | | | | | --- | --- | --- | --- | --- | --- | --- | | 000615 *ST美谷 | -816.02万 | -34.93% | 325.27万 | 13.92% | 490.75万 | 21.01% | | 688363 华熙生物 | -2980.80万 | -12.87% | 1401.94万 | 6.05% | 1578.86万 | 6.82% | | 300896 爱美客 | -9072.07万 | -14.75% | 570.74万 | 0.93% | 8501.33万 | 13.82% | | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688363 | 华熙生物 | 57.98 | -0.77% | 3.99万 | | 2.32 Z | | 000615 | *ST美谷 | 3.09 | -1.28% | 7.53万 | | 2336.03万 | | 300896 | 爱美客 | 189. ...